At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Lithium Carbonate +2 moredrug
Likely dose
Lithium Carbonate 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders
In Brief
A Phase 2 clinical trial evaluating Lithium Carbonate, Placebo, and 1 other intervention for Major Depressive Disorder and 3 related conditions. Completed, enrolled 80 participants across 2 sites.
Detailed Summary
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedAug 2010
Primary CompletionJan 2011
TodayJul 2026
First PostedAug 27, 2010
Enrollment StartMar 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.8 years ago
Interventions
Lithium Carbonatedrug
300 mg one time per day for 4 weeks
Placebodrug
Take one time daily for 4 weeks
Citalopramdrug
All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)